Stribild (Elvitegravir/Cobicistat/FTC/Tenofovir)
| Brand Name: |
Stribild |
| Generic Name: |
Elvitegravir/Cobicistat
/FTC/Tenofovir |
| Adult Single Dose: |
One tablet (containing 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 300 mg of tenofovir disoproxil fumarate) taken once daily |
| Food & Liquid Restrictions: |
Take with food |
| Drug Class: |
1 Integrase inhibitor + PK enhancer + 2 NRTIs |
|
|
|
The Basics
News
- AIDS Healthcare Foundation Challenges Gilead Over AIDS Drug Price Gouging of U.S. Government Programs on Stribild (February 1, 2013)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Stribild (the Quad) Approved in Canada (November 28, 2012)
From Canadian AIDS Treatment Information Exchange
- Stribild Gets FDA Approval as New Single-Tablet Regimen (November/December 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- FDA Approves Quad in U.S.: Price May Prohibit UK Access (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 Stribild ("Quad") Recommended as Alternative First-Line HIV Treatment Regimen by U.S. Guidelines Panel (September 18, 2012)
From TheBody.com
- ADAP Crisis Task Force and Gilead Sciences Agree on Stribild Pricing for ADAPs (September 10, 2012)
In Positively Aware, from Test Positive Aware Network
- Stribild Included in Co-Pay and Assistance Programs (September 10, 2012)
In Positively Aware, from Test Positive Aware Network
 Thoughts on "Quad" Approval by FDA (August 28, 2012)
From Journal Watch
On TheBodyPRO.com
- Food and Drug Administration Approves Once-a-Day Pill for HIV (August 28, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
 Stribild (a.k.a. "Quad") Approved by FDA for First-Line Use; Becomes Third Single-Pill Regimen (August 27, 2012)
From U.S. Food and Drug Administration
VIEW ALL ARTICLES
Research
- Updated Results on Quad: 96-Week Data From Phase 3 Studies (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
 Top 10 HIV Clinical Developments of 2012 (December 2012)
In HIV JournalView, from TheBodyPRO.com
- Dolutegravir and the 88 Percent Rule (October 28, 2012)
From Journal Watch
On TheBodyPRO.com
- Study Summaries From ICAAC 2012 (September/October 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Stribild (a.k.a. "Quad") Performs Well for People Over 50, Study Finds (September 23, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
- Stribild (a.k.a. "Quad") May Slightly Outperform Other Popular First-Line Options, Study Finds (September 15, 2012)
In The 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012), from TheBodyPRO.com
- Integrated Analysis Shows "Quad" Pill Has Potent Activity With Fewer Side Effects (September 12, 2012)
From aidsmap.com
- Stribild "Quad" Pill Has Potent Anti-HIV Activity With Fewer Side Effects (September 11, 2012)
From HIVandHepatitis.com
- Studies Find Once-Daily "Quad" Is Safe and Effective (September/October 2012)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
On TheBodyPRO.com
- Quad Matches Atripla and Atazanavir Regardless of Viral Load or CD4 Count (August 17, 2012)
From HIVandHepatitis.com
VIEW ALL ARTICLES
|
Advertisement
|
Email
Glossary
